Tenax Therapeutics Inc expected to post a loss of 16  cents a share - Earnings Preview

Tenax Therapeutics

25/03/2022 11:21

* Tenax Therapeutics Inc  TENX.OQ   TENX.O  is expected
to show no
change in quarterly revenue when it reports  results on March 29
(estimated). 
    * ​Refinitiv's mean analyst estimate for Tenax Therapeutics
Inc is
for a loss of 16 cents per share. For the same quarter last
year, the company reported a loss of 60 cents per share.
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tenax
Therapeutics Inc is $4.75​, above​ its last closing price
of $0.70. ​​​

This summary was machine generated March 25 at 11:21 GMT.  All
figures in US dollars  unless otherwise stated